Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Natera Inc (NQ: NTRA )

120.16 USD +4.25 (+3.67%)
Official Closing Price Updated: 5:48 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Natera Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
New Data at the 2021 ASTS Winter Symposium to Showcase Benefit of Serial Prospera™ Testing
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on the Prospera test at the American Society of Transplant Surgeons... 
From PR Newswire
Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium
Oral presentation showcases the largest early-stage CRC cohort to date, further validating the serial use of Signatera™ for early recurrence detection and MRD assessment 
From PR Newswire
Natera to Webcast Live Presentation at the 39th Annual J.P. Morgan Healthcare Conference
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 39th Annual J.P. Morgan Healthcare Conference on... 
From PR Newswire
U.S. Patent Office Upholds Validity of Natera's Early Priority Date '592 cfDNA Patent
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, is pleased that the United States Patent Office granted Natera a significant win when it denied a... 
From PR Newswire
New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial
Oral presentation will show that Signatera can identify MIUC patients likely to benefit from adjuvant treatment with atezolizumab 
From PR Newswire
Natera to Present New Immunotherapy Monitoring Data at SABCS 2020
Two new studies in breast cancer demonstrate potential of Natera's technology to predict response to neoadjuvant immunotherapy and discover new treatment resistance mechanisms 
From PR Newswire
Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of... 
From PR Newswire
Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United States has extended coverage of NIPT to all pregnancies. 
From PR Newswire
New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients
Study published in Annals of Oncology validates Signatera™ for use in neoadjuvant treatment response monitoring 
From PR Newswire
Natera Appoints Dr. Monica Bertagnolli to its Board of Directors
Former president and current board member of ASCO brings deep oncology expertise and leadership 
From PR Newswire
Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on... 
From PR Newswire
Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring
Clinical case studies demonstrate the performance of the Signatera™ test in cancer patients receiving immunotherapy 
From PR Newswire
Natera Reports Third Quarter 2020 Financial Results
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent... 
From PR Newswire
International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin Pregnancies
Recommends incorporating zygosity, a capability unique to the Panorama® test, into clinical practice 
From PR Newswire
Natera Announces Third Quarter 2020 Earnings Conference Call
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2020, after the market close on... 
From PR Newswire
NIPT for Average Risk Now Covered for 139 Million Commercial Lives
Top 5 payor changes medical policy following recent ACOG guideline 
From PR Newswire
Natera to Present New Data at ASN Kidney Week 2020 Showing Clinical Differentiation of the Prospera™ Test
Represents largest dd-cfDNA retransplant study to date and demonstrates clinical value of proprietary background cfDNA technology 
From PR Newswire
Natera's Panorama® NIPT Receives Average Risk Coverage for an Additional 24 Million Lives
Fourth largest health plan adopts average risk coverage post-ACOG and SMFM guideline change 
From PR Newswire
Natera Teams Up with the George Lopez Foundation on the #GLFTrickShot Kidney Disease Awareness Challenge
Celebrities and the public are making creative golf trick shot videos to create awareness and encourage donations for kidney disease patients 
From PR Newswire
Court Rejects ArcherDX's Motion to Dismiss Natera's Patent Infringement Case
Upholds validity of Natera's patents; patent case against ArcherDX continues 
From PR Newswire
Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera™
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced that its Signatera molecular residual disease (MRD) test will be used in the DARE study, a multi-center... 
From PR Newswire
Medicare Issues Draft Local Coverage Determination for Signatera™ in Immunotherapy Response Monitoring
Proposes expanded coverage of the Signatera minimal residual disease (MRD) test in a broad range of solid tumor types and indications including immunotherapy (IO) monitoring 
From PR Newswire
Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting
1 oral and 3 poster presentations demonstrate effectiveness of Signatera™ in stage IV oligometastatic colorectal cancer (CRC), stage I-III CRC, and esophageal adenocarcinomas 
From PR Newswire
Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation
Innovative technology platform for cell-free DNA testing in oncology and organ transplantation uniquely positions Natera to help improve outcomes for the most vulnerable transplant patients 
From PR Newswire
Natera's Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative Contractor (MAC) for Northern California, has finalized a... 
From PR Newswire
Natera Announces Pricing of Follow-On Offering
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 4,166,666 shares of its common stock at a price to the public... 
From PR Newswire
Natera to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Morgan Stanley 18th Annual Global Healthcare Conference... 
From PR Newswire
Natera Launches Proposed Follow-On Offering
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock. In addition,... 
From PR Newswire
Natera Receives Final Medicare Coverage for its Signatera™ MRD Test in Stage II-III Colorectal Cancer
Creates patient access to first-of-its-kind, personalized ctDNA test to inform adjuvant treatment decisions and detect recurrence earlier than standard diagnostic tools 
From PR Newswire
SMART Study Data for Aneuploidy and 22q Unblinded
Natera extends NIPT technology leadership with new Panorama® artificial intelligence platform 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.